Figure 2From: Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study Rash vs. no rash. Kaplan-Meier analyses of time to progression (a) and survival since initiating TKI therapy (b) in months among patients that developed a skin rash (solid line) and patients that did not developed rash (dashed line).Back to article page